1921
Volume 95, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract

Hepatitis C virus (HCV)/ coinfection is common in Egypt and other developing countries. This study aimed to investigate the influence of HCV/ coinfection on the concentration of HCV–nonstructural protein-4 (NS4) in addition to collagen III and matrix metalloproteinase-1 (MMP-1) in different hepatic fibrosis stages. We found that coinfected patients ( = 186) showed significantly ( < 0.05, Mann–Whitney test) higher concentrations of HCV-NS4, collagen III, and collagen III/MMP-1 ratio (CMR) than those with HCV monoinfection ( = 104) in different fibrosis stages. Conversely, coinfected patients showed significantly lower concentrations of MMP-1 when compared with HCV monoinfection. The elevated levels of CMR in case of HCV monoinfection yielded an estimated odds ratio of 1.8 and 2.6 for developing significant fibrosis (F2-F4) and cirrhosis (F4), respectively. HCV/ coinfection increased the risk for developing F2-F4 and F4 several fold yielding an estimated odds ratio of 11.1 and 5.2, respectively. This means that coinfected patients have a 6-fold and 2-fold increased risk of developing F2-F4 and F4, respectively, over HCV-monoinfected patients. Thus, elevated levels of HCV-NS4 and CMR in HCV/ coinfection suggest increased susceptibility of coinfected patients, compared with those with HCV monoinfection, for accelerating hepatic fibrosis progression.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.16-0129
2016-11-02
2018-12-12
Loading full text...

Full text loading...

/deliver/fulltext/14761645/95/5/1044.html?itemId=/content/journals/10.4269/ajtmh.16-0129&mimeType=html&fmt=ahah

References

  1. European Association for Study of Liver, 2014. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 60: 392420.[Crossref] [Google Scholar]
  2. Negro F, , 2014. Curbing hepatitis C virus spread in Egypt. Lancet Glob Health 2: e495e496.[Crossref] [Google Scholar]
  3. Lavanchy D, , 2011. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 17: 107115.[Crossref] [Google Scholar]
  4. Gryseels B, , 2012. Schistosomiasis. Infect Dis Clin North Am 26: 383397.[Crossref] [Google Scholar]
  5. Colley DG, Bustinduy AL, Secor WE, King CH, , 2014. Human schistosomiasis. Lancet 383: 22532264.[Crossref] [Google Scholar]
  6. Sanghvi MM, Hotez PJ, Fenwick A, , 2013. Neglected tropical diseases as a cause of chronic liver disease: the case of schistosomiasis and hepatitis C co-infections in Egypt. Liver Int 33: 165168.[Crossref] [Google Scholar]
  7. Attallah AM, Yones E, Ismail H, El Masry SA, Tabll A, Elenein AA, El Ghawalby NA, , 1999. Immunochemical characterization and diagnostic potential of a 63-kilodalton Schistosoma antigen. Am J Trop Med Hyg 60: 493497. [Google Scholar]
  8. Strickland GT, , 2006. Liver disease in Egypt: hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors. Hepatol 43: 915922.[Crossref] [Google Scholar]
  9. Van-Lume DS, Albuquerque M de F, Souza AI, Domingues AL, Lopes EP, Morais CN, Montenegro SM, , 2013. Association between schistosomiasis mansoni and hepatitis C: systematic review. Rev Saude Publica 47: 414424.[Crossref] [Google Scholar]
  10. Brady MT, MacDonald AJ, Rowan AG, Mills KH, , 2003. Hepatitis C virus non‐structural protein 4 suppresses Th1 responses by stimulating IL‐10 production from monocytes. Eur J Immunol 33: 34483457.[Crossref] [Google Scholar]
  11. Attallah AM, Omran MM, Nasif WA, Ghaly MF, El-Shanshoury AER, Abdalla MS, Sharada HM, Farid K, El-Shony W, Moussa ESM, El-Domany EB, Nour E, Eldosoky I, , 2012. Diagnostic performances of hepatitis C virus-NS4 antigen in patients with different liver pathologies. Arch Med Res 43: 555562.[Crossref] [Google Scholar]
  12. Chen CZ, Raghunath M, , 2009. Focus on collagen: in vitro systems to study fibrogenesis and antifibrosis state of the art. Fibrogenesis Tissue Repair 2: 7.[Crossref] [Google Scholar]
  13. Arthur MJP, , 1994. Degradation of matrix proteins in liver fibrosis. Pathol Res Pract 190: 825833.[Crossref] [Google Scholar]
  14. Attallah AM, El-Far M, Abdel Malak CA, Omran MM, Farid K, Hussien MA, Albannan MS, Attallah AA, Elbendary MS, Elbesh DA, Elmenier NA, Abdallah MO, , 2015. Fibro-check: a combination of direct and indirect markers for liver fibrosis staging in chronic hepatitis C patients. Ann Hepatol 14: 225233.[Crossref] [Google Scholar]
  15. Poynard T, Bedossa P, Opolon P, , 1997. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349: 825832.[Crossref] [Google Scholar]
  16. Laemmli UK, , 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680685.[Crossref] [Google Scholar]
  17. Towbin H, Staehelin T, Gordon J, , 1979. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 76: 43504354.[Crossref] [Google Scholar]
  18. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ, , 1951. Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265275. [Google Scholar]
  19. European Association for Study of Liver, 2015. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 63: 199236.[Crossref] [Google Scholar]
  20. Strader DB, Wright T, Thomas DL, Seeff LB, , 2004. Diagnosis, management, and treatment of hepatitis C. Hepatol 39: 11471171.[Crossref] [Google Scholar]
  21. Booth JC, O'Grady J, Neuberger J, , 2001. Clinical guidelines on the management of hepatitis C. Gut 49: I1I21.[Crossref] [Google Scholar]
  22. Vilstrup H, , 2003. Cirrhosis and bacterial infections. Rom J Gastroenterol 12: 297302. [Google Scholar]
  23. Mengshol JA, Golden-Mason L, Rosen HR, , 2007. Mechanisms of disease: HCV-induced liver injury. Nat Clin Pract Gastroenterol Hepatol 4: 622634.[Crossref] [Google Scholar]
  24. Bataller R, Paik YH, Lindquist JN, Lemasters JJ, Brenner DA, , 2004. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterol 126: 529540.[Crossref] [Google Scholar]
  25. Shin JY, Hur W, Wang JS, Jang JW, Kim CW, Bae SH, Jang SK, Yang SH, Sung YC, Kwon OJ, Yoon SK, , 2005. HCV core protein promotes liver fibrogenesis via up-regulation of CTGF with TGF-beta1. Exp Mol Med 37: 138145.[Crossref] [Google Scholar]
  26. Arthur MJ, Mann DA, Iredale JP, , 1998. Tissue inhibitors of metalloproteinases, hepatic stellate cells and liver fibrosis. J Gastroenterol Hepatol 13: S33S38. [Google Scholar]
  27. Leroy V, Monier F, Bottari S, Trocme C, Sturm N, Hilleret MN, Morel F, Zarski JP, , 2004. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol 99: 271279.[Crossref] [Google Scholar]
  28. Bataller R, Brenner DA, , 2005. Liver fibrosis. J Clin Invest 115: 209218.[Crossref] [Google Scholar]
  29. Kamal SM, Turner B, He Q, Rasenack J, Bianchi L, Al Tawil A, Nooman A, Massoud M, Koziel MJ, Afdhal NH, , 2006. Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis. Hepatol 43: 771779.[Crossref] [Google Scholar]
  30. Inagaki Y, Okazaki I, , 2007. Emerging insights into transforming growth factor beta Smad signal in hepatic fibrogenesis. Gut 56: 284292.[Crossref] [Google Scholar]
  31. Jarcuska P, Janicko M, Veseliny E, Jarcuska P, Skladaný L, , 2010. Circulating markers of liver fibrosis progression. Clin Chim Acta 411: 10091017.[Crossref] [Google Scholar]
  32. Knittel T, Mehde M, Kobold D, Saile B, Dinter C, Ramadori G, , 1999. Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and non-parenchymal cells of rat liver: regulation by TNF-alpha and TGF-beta1. J Hepatol 30: 4860.[Crossref] [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.16-0129
Loading
/content/journals/10.4269/ajtmh.16-0129
Loading

Data & Media loading...

  • Received : 19 Feb 2016
  • Accepted : 13 Jul 2016

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error